Are lifestyle interventions in primary care cost-effective? - An analysis based on a Markov model, differences-in-differences approach and the Swedish Björknäs study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Saha, Sanjib ^a,b   Carlsson, Katarina Steen ^a   Gerdtham, Ulf G ^a,b   Eriksson, Margareta K ^c,d   Hagberg, Lars ^e   Eliasson, Mats ^f   Johansson, Pia ^g  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c Norrbotten County Council   (Sweden)

^d LULEÅ UNIVERSITY OF TECHNOLOGY   (Sweden)

^e ÖREBRO UNIVERSITY   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROBABILITY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LIFE STYLE; MALE; MARKOV CHAINS; MIDDLE AGED; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RISK REDUCTION BEHAVIOR;

EID: 84893569579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080672     Document Type: Article

References (60)

1. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA et al. (2011) The effect of mediterranean diet on metabolic syndrome and its components: A meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 57: 1299-1313. doi:10.1016/j.jacc.2010.09.073. PubMed: 21392646.
2. Churilla JR, Zoeller RF (2008) Physical Activity: Physical Activity and the Metabolic Syndrome: A Review of the Evidence. Am J Lifestyle Med 2: 118-125. doi:10.1177/1559827607311981.
3. Horton ES (2009) Effects of Lifestyle Changes to Reduce Risks of Diabetes and Associated Cardiovascular Risks: Results from Large Scale Efficacy Trials. Obesity 17: S43-S48. doi:10.1038/oby.2009.388. PubMed: 19927146.
4. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K et al. (2001) Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care 24: 683-689. doi:10.2337/diacare.24.4.683. PubMed: 11315831. (Pubitemid 32893993)
5. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM (2003) The Metabolic Syndrome as Predictor of Type 2 Diabetes: The San Antonio Heart Study. Diabetes Care 26: 3153-3159. doi:10.2337/diacare.26.11.3153. PubMed: 14578254. (Pubitemid 37339513)
6. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD et al. (2011) Heart Disease and Stroke Statistics - 2011. Update / 1. About 1. About These Statistics / 2 American Heart Association's 2020 Impact Goals / 3. Cardiovascular Diseases / 4. Subclinical Atherosclerosis / 5. Coronary Heart Disease, Acute Coronary Syndrome, and Angina Pectoris / 6. Stroke (Cerebrovascular Disease) / 7. High Blood Pressure / 8. Congenital Cardiovascular Defects / 9. Cardiomyopathy and Heart Failure / 10. Other Cardiovascular Diseases / 11. Family History and Genetics / 12. Risk Factor: Smoking/Tobacco Use / 13. Risk Factor: High Blood Cholesterol and Other Lipids / 14. Risk Factor: Physical Inactivity / 15. Risk Factor: Overweight and Obesity / 16. Risk Factor: Diabetes Mellitus / 17. End-Stage Renal Disease and Chronic Kidney Disease / 18. Metabolic Syndrome / 19. Nutrition / 20. Quality of Care / 21. Medical Procedures / 22. Economic Cost of Cardiovascular Disease / 23. At-a-Glance Summary Tables / 24. Glossary. Circulation 123: e18-e209
7. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M et al. (2009) Metabolic syndrome and cardiometabolic risk: An update. Blood Press 18: 7-16. doi:10.1080/08037050802677695. PubMed: 19148840.
8. Hollman G, Kristenson M (2008) The prevalence of the metabolic syndrome and its risk factors in a middle-aged Swedish population - Mainly a function of overweight? Eur J Cardiovasc Nurs 7: 21-26. doi:10.1016/j.ejcnurse.2008.01.039. PubMed: 17586094. (Pubitemid 351217070)
9. Welin L, Adlerberth A, Caidahl K, Eriksson H, Hansson PO et al. (2008) Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. BMC Public Health 8: 403. doi:10.1186/1471-2458-8-403. PubMed: 19063738.
10. Saha S, Gerdtham UG, Johansson P (2010) Economic Evaluation of Lifestyle Interventions for Prevention of Diabetes and Cardiovascular Diseases. Int J Environ Res Public Health 7: 3150-3159. doi:10.3390/ijerph7083150. PubMed: 20948954.
11. Eriksson KM, Westborg CJ, Eliasson MC (2006) A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors. Scand J Public Health 34: 453-461. doi:10.1080/14034940500489826. PubMed: 16990155.
12. Eriksson MK, Franks PW, Eliasson M (2009) A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting:The Swedish Bjorknas study. PLOS ONE 4: e5195. doi:10.1371/journal.pone. 0005195. PubMed: 19365563.
13. Banta HD, de Wit GA (2008) Public Health Services and Cost-Effectiveness Analysis. Annu Rev Public Health 29: 383-397. doi:10.1146/annurev.publhealth.29. 020907.090808. PubMed: 18173390. (Pubitemid 351600415)
14. Griffin S, Rice N, Sculpher M (2009) Economic evaluation of public health interventions. In: A Kelly. Evidence-based Public Health. Oxford: Oxford University Press. pp. 111-127.
15. the Swedish National Board of Health and Welfare National Guidelines for Methods of Preventing Disease - summary. Available: http://www.socialstyrelsen. se/nationalguidelines/nationalguidelinesformethodsofpreventingdisease. (Accessed 30.01.2013).
16. Ashenfelter O, Card D (1985) Using the Longitudinal Structure of Earnings to Estimate the Effect of Training Programs. Rev Econ Statist 67: 648-660. doi:10.2307/1924810.
17. Bassanini A, Venn D (2007) Assessing the impact of labour market policies on productivity: a difference-in-differences approach. OECD Publishing.
18. Rodríguez-Oreggia E (2012) Hurricanes and labor market outcomes: Evidence for Mexico. Glob Environ Change 1: 351-359.
19. Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA et al. (2007) Cost-Effectiveness of Diabetes Case Management for Low-Income Populations. Health Serv Res 42: 1943-1959. doi:10.1111/j.1475-6773.2007.00701.x. PubMed: 17850527. (Pubitemid 47397181)
20. Li G, Zhang P, Wang J, Gregg EW, Yang W et al. (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371: 1783-1789. doi:10.1016/S0140-6736(08)60766-7. PubMed: 18502303. (Pubitemid 351697954)
21. Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L et al. (2010) Interventions to Promote Physical Activity and Dietary Lifestyle Changes for Cardiovascular Risk Factor Reduction in Adults: A Scientific Statement From the American Heart Association. Circulation 122: 406-441. doi:10.1161/CIR.0b013e3181e8edf1. PubMed: 20625115.
22. Brown CH, Baidas SM, Hajdenberg JJ, Kayaleh OR, Pennock GK et al. (2009) Lifestyle Interventions in the Prevention and Treatment of Cancer. Am J Lifestyle Med 3: 337-348. doi:10.1177/1559827609334983.
23. Mattila R, Malmivaara A, Kastarinen M, Kivelä SL, Nissinen A (2004) Effects of lifestyle intervention on neck, shoulder, elbow and wrist symptoms. Scand J Work Environ Health 30: 191-198. doi:10.5271/sjweh.779. PubMed: 15250647. (Pubitemid 38931178)
24. Walsh R (2011) Lifestyle and mental health. Am Psychol 66: 579-592. doi:10.1037/a0021769. PubMed: 21244124.
25. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson EB, Osterlind J et al. (2010) Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med 170: 1470-1479. doi:10.1001/archinternmed.2010.301. PubMed: 20837834.
26. Sculpher MJ, Claxton K, Drummond M, McCabe C (2006) Whither trial-based economic evaluation for health care decision making? Health Econ 15: 677-687. doi:10.1002/hec.1093. PubMed: 16491461. (Pubitemid 44057239)
27. Li G, Zhang P, Wang J, Gregg EW, Yang W et al. (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371: 1783-1789. doi:10.1016/S0140-6736(08)60766-7. PubMed: 18502303. (Pubitemid 351697954)
28. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG et al. (2008) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368: 1673-1679. PubMed: 17098085.
29. Galani C, Schneider H, Rutten FF (2007) Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland. Int J Public Health 52: 372-382. doi:10.1007/s00038-007- 7014-9. PubMed: 18369000. (Pubitemid 351166079)
30. Herman WH, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM (2005) The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med: 2005: 323-332 (Pubitemid 40293405)
31. Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM et al. (2007) Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 30: 128-134. doi:10.2337/dc06-0690. PubMed: 17192345.
32. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE et al. (2004) Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical Therapeutics 26: 304-321. doi:10.1016/S0149-2918(04)90029-X. PubMed: 15038953. (Pubitemid 38339022)
33. Eddy DM, Schlessinger L, Kahn R (2005) Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes. Ann Intern Med 143: 251-264. doi: 10.7326/0003-4819-143-4-200508160-00006. PubMed: 16103469.
34. Johansson P, Östenson C-G, Hilding AM, Andersson C, Rehnberg C et al. (2009) A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden. Int J Technol Assess Health Care 25: 350-358. doi:10.1017/S0266462309990079. PubMed: 19619354.
35. Feldman I, Hellström L, Jojhansson P (2013) Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups-primary care patients in Sweden. Cost Effectiveness Res Allocation 11: 19
36. Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121: 293-298
37. Stern MP, Williams K, Haffner SM (2002) Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? Ann Intern Med 136: 575-581. doi:10.7326/0003-4819-136-8-200204160-00006. PubMed: 11955025. (Pubitemid 34407041)
38. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P et al. (2004) A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47: 1747-1759. doi:10.1007/s00125-004-1527-z. PubMed: 15517152. (Pubitemid 40022410)
39. Feldman I, Johansson P, Lund C (2009) A model for economic evaluations of metabolic syndrome interventions. Tech Rep
40. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press.
41. Statistics Sweden Consumer Price Index (CPI), Aavailable at http://www.scb.se/Pages/TableAndChart. Retrieved onpublished at whilst December year 1111 from -272152.aspx. (Accessed 30.02.2013)
42. Carlsson P, Anell A, Eliasson M (2006) Hälsoekonomi får allt större roll för sjukvårdens prioriteringar. Läkartidningen.
43. Bank World GDP per capita. Avaialble at http://data.worldbank.org/ indicator/NY.GDP.PCAP.CD, (Accessed on 30.02.2013).
44. WHO (2005) CHOosing Intervention that are Cost Effective (WHO-CHOICE) World Health Organization. Available: http://www.who.int/choice/costs/CER- levels/en/index.html. (Accessed 14.11.2012).
45. Wood AM, White IR, Thompson SG (2004) Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials 1: 368-376. doi:10.1191/1740774504cn032oa. PubMed: 16279275.
46. Lavori PW, Dawson R, Shera D (1995) A multiple imputation strategy for clinical trials with truncation of patient data. Statist Med 14: 1913-1925. doi:10.1002/sim.4780141707. PubMed: 8532984.
47. Rubin D (1987) Multiple Imputation for Nonresponse in Surveys. New York: Wiley & Sons.
48. Löfroth E, Lindholm L, Wilhelmsen L, Rosén M (2006) Optimising health care within given budgets: Primary prevention of cardiovascular disease in different regions of Sweden. Health Policy 75: 214-229. doi:10.1016/j.healthpol.2005.03.008. PubMed: 16005539.
49. DPP group (2003) Within-Trial Cost-Effectiveness of Lifestyle Intervention or Metformin for the Primary Prevention of Type 2 Diabetes. Diabetes Care 26: 2518-2523
50. Lindgren P, Lindström J, Tuomilehto J, Uusitupa M, Peltonen M et al. (2007) Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care 23: 177-183. PubMed: 17493303. (Pubitemid 46642725)
51. Hagberg LA, Lindholm L (2005) Is promotion of physical activity a wise use of societal resources? Issues of cost-effectiveness and equity in health. Scand J Med Sci Sports 15: 304-312. doi:10.1111/j.1600-0838.2004.00415.x. PubMed: 16181254. (Pubitemid 41426405)
52. Fappa E, Yannakoulia M, Pitsavos C, Skoumas I, Valourdou S et al. (2008) Lifestyle intervention in the management of metabolic syndrome: could we improve adherence issues? Nutrition 24: 286-291. doi:10.1016/j.nut.2007.11.008. PubMed: 18201869.
53. Finkelstein EA, Khavjou O, Will JC (2006) Cost-Effectiveness of WISEWOMAN, a Program Aimed at Reducing Heart Disease Risk among Low-Income Women. J Womens Health 15: 379-389. doi:10.1089/jwh.2006.15.379. PubMed: 16724886. (Pubitemid 43891168)
54. Lindgren P, Fahlstadius P, Hellenius M-L, Jönsson B, de Faire U (2003) Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm - a stochastic model of exercise and dietary advice. Prev Med 36: 403-409. doi:10.1016/S0091-7435(02)00060-9. PubMed: 12649048. (Pubitemid 36315792)
55. Colagiuri S, Walker AE (2008) Using An Economic Model Of Diabetes To Evaluate Prevention And Care Strategies In Australia. Health Aff 27: 256-268. doi:10.1377/hlthaff.27.1.256. PubMed: 18180502. (Pubitemid 351198609)
56. Salkeld G, Phongsavan P, Oldenburg B, Johannesson M, Convery P et al. (1997) The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 41: 105-119. doi:10.1016/S0168-8510(97)00015-8. PubMed: 10169297. (Pubitemid 27321959)
57. Van Baal PH, Van den Berg M, Hoogenveen RT, Vijgen SM, Engelfriet PM (2008) Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health 11: 1033-1040. doi:10.1111/j.1524-4733.2008.00328.x. PubMed: 18494748.
58. Wallerstedt SM, Bladh L, Ramsberg J (2012) A cost-effectiveness analysis of an in-hospital clinical pharmacist service. BMJ Open 2: 1.
59. Grundy SM (2007) Metabolic syndrome: A multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92: 399-404. PubMed: 17284640.
60. Kahn R, Buse J, Ferrannini E, Stern M (2005) The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289-2304. doi:10.2337/diacare.28.9.2289. PubMed: 16123508.